Cargando…
CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial
BACKGROUND: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Here we conducted a phase 2, multicenter, randomized, controlled trial, comparing the efficacy and safety of CEOP/IVE/GDP alternating regimen wi...
Autores principales: | Cai, Ming-Ci, Cheng, Shu, Wang, Xin, Hu, Jian-Da, Song, Yong-Ping, Huang, Yao-Hui, Yan, Zi-Xun, Jiang, Yu-Jie, Fang, Xiao-Sheng, Zheng, Xiao-Yun, Dong, Li-Hua, Ji, Meng-Meng, Wang, Li, Xu, Peng-Peng, Zhao, Wei-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191773/ https://www.ncbi.nlm.nih.gov/pubmed/32349779 http://dx.doi.org/10.1186/s13073-020-00739-0 |
Ejemplares similares
-
Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021) -
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
por: Al-Sarayfi, Diana, et al.
Publicado: (2022) -
Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004) -
Controlled Education of patients after Stroke (CEOPS)- nurse-led multimodal and long-term interventional program involving a patient’s caregiver to optimize secondary prevention of stroke: study protocol for a randomized controlled trial
por: Mendyk, Anne-Marie, et al.
Publicado: (2018) -
GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
por: Wang, Jing-jing, et al.
Publicado: (2016)